...
【24h】

Microscopic Polyangiitis

机译:显微镜下多血管炎

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Microscopic polyangiitis is a systemic vasculitis affecting small- and medium-sized vessels and is characteristically associated with a focal and segmental necrotizing glomerulonephritis. It may present as a pulmonary-renal syndrome with rapidly progressive glomerulonephritis and alveolar hemorrhage, but the pattern of disease will vary according to the organ systems involved. Granulomatous disease of the upper or lower respiratory tract is not a feature, and its presence suggests the diagnosis of Wegener's granulomatosis. The etiology of the condition is unclear, but most patients have anti-neutrophil cytoplasm antibodies (ANCA) with specificity for either myeloperoxidase (MPO) or proteinase 3 (PR3), and there is increasing evidence that these may be pathogenic. Current treatment includes an induction phase using cyclophosphamide and steroids to attain remission, followed by a maintenance phase in which the levels of immunosuppression are gradually reduced. Azathioprine may be substituted for cyclophosphamide at 3 months. Adjunctive plasma exchange or intravenous methylprednisolone is used in the management of either or both severe renal disease and alveolar hemorrhage, and new evidence suggests that plasma exchange is more effective in recovery of renal function. Overall, 1-year survival in systemic vasculitis is around 85%, and up to 50% of patients relapse, although relapse is less common in those with MPO-ANCA. Newer therapies are being explored in an attempt to increase the efficacy and reduce the toxicity of treatment.
机译:显微镜下多血管炎是一种影响中小血管的全身性血管炎,特征是与局灶性和节段性坏死性肾小球肾炎相关。它可能表现为具有快速进行性肾小球肾炎和肺泡出血的肺肾综合征,但疾病的类型会根据所涉及的器官系统而变化。上呼吸道或下呼吸道肉芽肿性疾病不是特征,它的存在提示韦格纳肉芽肿病的诊断。该病的病因尚不清楚,但是大多数患者都具有对髓过氧化物酶(MPO)或蛋白酶3(PR3)具有特异性的抗中性粒细胞胞浆抗体(ANCA),并且越来越多的证据表明它们可能是致病的。当前的治疗包括使用环磷酰胺和类固醇达到缓解的诱导期,然后是维持阶段,其中免疫抑制水平逐渐降低。硫唑嘌呤可以在3个月后取代环磷酰胺。辅助血浆置换或静脉内甲基强的松龙用于严重肾脏疾病和肺泡出血中的一种或两种的治疗,新证据表明血浆置换对恢复肾功能更有效。总体而言,系统性血管炎的1年生存率约为85%,高达50%的患者复发,尽管MPO-ANCA患者的复发较少。正在探索新的疗法,以试图提高疗效并降低治疗的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号